Cardiovascular Health

Chelation Vindicated for CVD Risk Reduction in Diabetes

By Erik Goldman

New data from the NIH-funded Trial to Assess Chelation Therapy (TACT), has vindicated this controversial treatment as a method for preventing cardiovascular events in people with diabetes. The data show a clear 15% reduction in index events among treated patients.

When Questioning Clinical Dogma Is a Doctor’s Duty

By Erik Goldman | Contributing Writer - Vol. 15, No. 2. Summer, 2013

Twenty years ago, Dr. Stephen Sinatra was like most American cardiologists: firmly convinced that elevated cholesterol was the key driver of heart disease, and that thanks to statin drugs, he and his colleagues would soon be cutting the nation’s number one killer down to size.

Drug Therapy Has Little Value In Early Stage Hypertension

By Erik Goldman
Amid the clamor over metanalyses suggesting that organic veggies are no more nutritious than conventional, and that omega-3's don't reverse heart disease, another important metanalysis got totally overlooked: the one showing that anti-hypertensive drugs are largely ineffective in people with Stage 1 hypertension.

Reckoning with Statin-Induced Diabetes and Metformin Resistance

By Thomas G. Guilliams, PhD, Contributing Writer - Vol. 13, No. 3. Fall, 2012

Drug therapies to reduce cardiovascular risk and prevent the onset of diabetes may be effective in the short term, but as people age, the efficacy of drugs like statins and metformin tends to diminish, while the risk of adverse effects increases. The benefit of nutritional and lifestyle interventions, on the other hand, remains robust even as people enter their final decades.